Drug Trial Radar · NCT07495007
An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Nov 10, 2025
Primary completion
Dec 28, 2025
Study completion Dec 28, 2025
Sponsor
- Lead sponsor
- Zi Diligence BiocenterIndustry
- Sponsor type
- Industry
- Collaborators
- Marcyrl Pharmaceutical Industries
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Bioequivalence study of two injectable formulation of progesterone in healthy post-menopausal women
Conditions
- Bioequivalance
- Post-menopause
Interventions
Progesterone IM of 100 mgDrug
Test Product
Progesterone IM of 100 mgDrug
Reference product
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 72 hours
- AUC0-TTime frame: 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zi Diligence Biocenter
Cairo, Cairo Governorate, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.